Review
Oncology
Mahmood Barani, Seyedeh Maryam Hosseinikhah, Abbas Rahdar, Leila Farhoudi, Rabia Arshad, Magali Cucchiarini, Sadanand Pandey
Summary: Bladder cancer is a common cancer in both men and women, and the use of nanotechnology has shown promising potential in improving the diagnosis and treatment of this disease. Nanoparticles offer a novel approach to enhance drug delivery and therapeutic performance, reducing the limitations of conventional cancer therapies. Developing nanosystems that can effectively diagnose and treat bladder cancer is crucial in advancing medical approaches in cancer management.
Review
Biotechnology & Applied Microbiology
Yadong Xu, Cheng Luo, Jieqiong Wang, Lingwu Chen, Junxing Chen, Tianfeng Chen, Qinsong Zeng
Summary: Bladder cancer remains a common malignancy with unsatisfactory theranostic approaches. Nanotechnology has shown promising potential in improving efficiency of diagnosis and treatment through targeted delivery of agents and distinguishing normal and abnormal bladder tissues. Future research on novel nanoparticles for bladder cancer management is encouraged.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Natalia Georgantzoglou, Alexandros Pergaris, Christos Masaoutis, Stamatios Theocharis
Summary: Exosomes, extracellular vesicles containing biomolecular cargo, play a crucial role in intercellular communication and oncogenesis. Urine is suggested as a rich source of exosomal biomarkers with potential applications in bladder cancer management. Further studies optimizing sample collection procedures and analytical methods are needed to enhance the diagnostic and therapeutic potential of exosomal biomarkers in bladder cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, General & Internal
Leah H. Biller, Deborah Schrag
Summary: Colorectal cancer is the third most common cause of cancer mortality worldwide. For patients diagnosed with metastatic colorectal cancer, approximately 70% to 75% can survive beyond 1 year. Tailoring treatments based on the molecular and pathologic features of the tumor has shown to improve overall survival rates.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Review
Nutrition & Dietetics
Fan Yang, Guanmo Liu, Jiaxin Wei, Yucheng Dong, Xuebin Zhang, Yongchang Zheng
Summary: Bladder cancer is a prevalent and widespread malignancy that affects the urinary system. The causes of bladder cancer include genetic factors, age, sex, and lifestyle factors such as imbalanced nutrition, obesity, and metabolic disorders. This review analyzes the close relationship between dietary nutrients and the onset and development of bladder cancer, with a focus on nutrients commonly consumed in daily life. It also examines the impact of nutritional intake before and after surgery on the recovery process of bladder cancer patients. The article aims to raise awareness about the importance of implementing appropriate dietary nutrition to reduce the risk of developing bladder cancer, improve perioperative care for patients, and aid in their recuperation.
Review
Urology & Nephrology
Anouk E. Hentschel, Emma E. van der Toom, Andre N. Vis, Johannes C. F. Ket, Judith Bosschieter, Martijn W. Heymans, R. Jeroen A. van Moorselaar, Renske D. M. Steenbergen, Jakko A. Nieuwenhuijzen
Summary: Urinary mutation analysis has shown promise as a diagnostic tool for non-invasive BC diagnosis, but there are substantial differences in diagnostic accuracy of urinary BC mutation markers among different studies. To translate the data summarized in this review to future clinical practice, heterogeneity in research design, BC population, mutation analysis technique, and urinary DNA must be taken into consideration.
Review
Oncology
Yongjun Yang, Chen Wang, Zonglin Li, Qiang Lu, Yuanwei Li
Summary: According to guidelines, transurethral resection of bladder tumor (TURBT) followed by intravesical therapy is the standard strategy for managing non-muscle invasive bladder cancer (NMIBC). However, the risk of recurrence and progression even with standard strategy is high. En bloc resection of bladder tumor (ERBT) removes the tumor tissue in one piece and protects its integrity and spatial orientation, allowing for accurate histopathological analysis. Combining ERBT with enhanced imaging and proteogenomics technology has the potential to achieve precise diagnosis and treatment of bladder cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Chemistry, Analytical
Chenfan Kong, Shaohua Zhang, Qifang Lei, Song Wu
Summary: This article presents an overview of the new advancements in nano-platforms for the diagnosis and treatment of bladder cancer, including the potential of nanomedicine in reducing side effects, enhancing tumor inhibition effects, and overcoming drug resistance.
Review
Cell Biology
Antonio J. Montero-Hidalgo, Jesus M. Perez-Gomez, Antonio J. Martinez-Fuentes, Enrique Gomez-Gomez, Manuel D. Gahete, Juan M. Jimenez-Vacas, Raul M. Luque
Summary: Bladder cancer is the most common malignancy of the urinary tract worldwide. The disease can be treated with surgery, chemotherapy, and immunotherapy, but many patients develop resistance to these treatments and experience aggressive metastasis with poor prognosis. The molecular heterogeneity of bladder cancer is a significant limitation, but the dysregulation of RNA splicing has been identified as a potential target for diagnosis, prognosis, and therapy. Targeting specific splicing factors, mRNA splicing variants, and circular RNAs has shown promising antitumor effects, offering new possibilities for improving the management of this devastating cancer type.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Review
Cell Biology
Seung-Hwan Jeong, Ja Hyeon Ku
Summary: This paper reviewed urinary markers for bladder cancer and compared their efficacies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Chemistry, Analytical
Angela Carapito, Ana Cecilia A. Roque, Felix Carvalho, Joana Pinto, Paula Guedes de Pinho
Summary: This review evaluates the potential of urinary volatile organic compounds (VOCs) as biomarkers for detecting and staging bladder cancer. The studies using gas chromatography-mass spectrometry (GC-MS) and electronic-nose (e-nose) sensors showed promising results in terms of sensitivity, specificity, and accuracy. Further studies are needed to validate these findings and improve the overall survival and quality of life for bladder cancer patients.
Article
Biophysics
Melanie MacGregor, Hanieh Safizadeh Shirazi, Kit Man Chan, Kola Ostrikov, Kym McNicholas, Alex Jay, Michael Chong, Alexander H. Staudacher, Thomas D. Michl, Aigerim Zhalgasbaikyzy, Michael P. Brown, Moein Navvab Kashani, Adam Di Fiore, Alex Grochowski, Stephen Robb, Simon Belcher, Jordan Li, Jonathan M. Gleadle, Krasimir Vasilev
Summary: The non-invasive diagnostic platform presented in this study combines microfluidic technology with PDD principles and immunocapture technology to detect shed bladder cancer cells in patient urine, achieving highly specific capture rates. In a pilot study, it successfully differentiated bladder cancer patients from non-cancer controls, showing potential for post-treatment surveillance and cancer detection in suspected bladder cancer patients.
BIOSENSORS & BIOELECTRONICS
(2021)
Review
Urology & Nephrology
Yanish Soorojebally, Yann Neuzillet, Mathieu Roumiguie, Pierre-Jean Lamy, Yves Allory, Francoise Descotes, Sophie Ferlicot, Diana Kassab-Chahmi, Stephane Oudard, Xavier Rebillard, Catherine Roy, Thierry Lebret, Morgan Roupret, Francois Audenet
Summary: This systematic review evaluated the clinical validity and utility of eleven urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up. The results suggested that urinary biomarkers may have a complementary role in bladder cancer diagnosis and NMIBC surveillance, but further confirmation of their clinical benefit is needed.
WORLD JOURNAL OF UROLOGY
(2023)
Review
Oncology
Xinzi Hu, Guangzhi Li, Song Wu
Summary: This article reviews the recent advances in the diagnosis and treatment of bladder cancer, including innovative cystoscopy techniques, tumor biomarker-based urine screening, and intravesical or systemic therapeutic strategies. Exploratory clinical studies offer promising candidates for bladder cancer treatment.
Review
Biochemistry & Molecular Biology
Mamello Sekhoacha, Keamogetswe Riet, Paballo Motloung, Lemohang Gumenku, Ayodeji Adegoke, Samson Mashele
Summary: Prostate cancer is a malignancy that affects men globally and presents either as localized or advanced disease. This article aims to provide a comprehensive overview of prostate cancer, including disease diagnosis, pathogenic gene mutations, and treatment options. Ongoing research is focusing on alternative treatment approaches such as traditional medicine, nanotechnologies, and gene therapy to combat prostate cancer, drug resistance, and reduce adverse effects.
Article
Management
Weiyu Li, Brian T. Denton, Todd M. Morgan
Summary: This article presents a finite-horizon partially observable Markov decision process (POMDP) approach to optimize biopsy decisions for patients under active surveillance for prostate cancer. The objective is to minimize the number of biopsies and the delay in detecting high-risk cancer. The study considers parameter ambiguity and patients' preference variability, and proposes two fast approximation algorithms for the model.
EUROPEAN JOURNAL OF OPERATIONAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
David Victorson, Todd Morgan, Alexander Kutikov, Kristian Novakovic, Shilajit Kundu, Bruriah Horowitz, Kathryn Jackson, Elizabeth Addington, Karly Murphy, Christina Sauer, Charles Brendler
Summary: Although active surveillance is commonly used to treat low risk prostate cancer, many patients and their partners experience psychosocial stressors. This study aims to examine the efficacy of mindfulness training compared to a health promotion control condition in men on active surveillance and their spouses.
CONTEMPORARY CLINICAL TRIALS
(2023)
Review
Urology & Nephrology
Tyler M. Seibert, Isla P. Garraway, Anna Plym, Brandon A. Mahal, Veda Giri, Michelle F. Jacobs, Heather H. Cheng, Stacy Loeb, Brian T. Helfand, Rosalind A. Eeles, Todd M. Morgan
Summary: Genetic risk assessment can be useful for early detection and prevention of prostate cancer. Rare pathogenic mutations, especially in DNA damage repair genes, increase prostate cancer risk. Common genetic variants can be combined into genetic risk scores, and a high genetic risk score is associated with higher prostate cancer risk. A healthy lifestyle may partially decrease the risk of lethal prostate cancer.
Review
Urology & Nephrology
Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Giorgio Gandaglia, Guillaume Ploussard, Michael S. Leapman, John L. Gore, Andrzej Paradysz, Derya Tilki, Axel S. Merseburger, Todd M. Morgan, Alberto Briganti, Ganesh S. Palapattu, Shahrokh F. Shariat
Summary: Mutations in BRCA1 and BRCA2 genes are associated with increased risk of prostate cancer, with BRCA2 mutations showing a stronger association. These mutations are also linked to more aggressive disease characteristics and higher mortality rates. Screening strategies for individuals with these mutations are still a subject of debate, and the long-term impact of prostate cancer screening in this population is unknown.
NATURE REVIEWS UROLOGY
(2023)
Article
Oncology
Jeannette M. Schenk, Menghan Liu, Marian L. Neuhouser, Lisa F. Newcomb, Yingye Zheng, Kehao Zhu, James D. Brooks, Peter R. Carroll, Atreya Dash, William J. Ellis, Christopher P. Filson, Martin E. Gleave, Michael Liss, Frances M. Martin, Todd M. Morgan, Andrew A. Wagner, Daniel W. Lin
Summary: Following a healthy dietary pattern after prostate cancer diagnosis does not significantly reduce the risk of disease progression among men managed by active surveillance. However, these dietary patterns have well-established protective effects on chronic diseases and mortality, making them a prudent choice for prostate cancer patients.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
(2023)
Editorial Material
Urology & Nephrology
Udit Singhal, Simpa S. Salami
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Udit Singhal, Brent K. Hollenbeck, Samuel D. Kaffenberger, Simpa S. Salami, Arvin K. George, Ted A. Skolarus, Jeffrey S. Montgomery, Daniela A. Wittmann, David C. Miller, John T. Wei, Ganesh S. Palapattu, James E. Montie, Rodney L. Dunn, Todd M. Morgan
Summary: This study compares the urinary and sexual function recovery in patients undergoing prostate cancer surgery between historical and contemporary practices. The results show that modern techniques have improved sexual function recovery, but there was no significant improvement in urinary function recovery.
JOURNAL OF UROLOGY
(2023)
Editorial Material
Medicine, General & Internal
Udit Singhal, Caroline Horrow, Aaron S. Kesselheim, Todd M. Morgan
Summary: Advances in precision medicine have led to changes in the availability of laboratory-developed tests. Stricter regulatory oversight may be necessary, and a proposed FDA rule could be an important initiative.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Kevin D. Li, Carissa E. Chu, Milan Patel, Maxwell V. Meng, Todd M. Morgan, Sima P. Porten
Summary: Using CxMonitor (CxM), a home urine test, can help patients skip scheduled cystoscopies, reducing the burden and costs of bladder cancer surveillance. The study showed that CxM-based management was safe and satisfactory during the coronavirus pandemic.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Meeting Abstract
Urology & Nephrology
Udit Singhal, Ralph Jiang, Daniel E. Spratt, Matthew Schipper, Simpa S. Salami, Stephanie Daignault-Newton, Rodney Dunn, Thomas J. Maatman, Brian R. Lane, Frank N. Burks, Paul Rodriguez, Eduardo Kleer, Richard Sarle, Felix Y. Feng, Michael L. Cher, Robert T. Dess, Todd M. Morgan
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Mark Farha, Srinivas Nallandhighal, Randy Vince, Brittney Cotta, Judith Stangl-Kremser, Daniel Triner, Todd M. Morgan, Ganesh S. Palapattu, Marcin Cieslik, Ulka Vaishampayan, Aaron M. Udager, Simpa S. Salami
Summary: This study aimed to characterize the tumor immune microenvironment (TIME) of localized ccRCC and identify a cluster of patients with poor prognosis and lower predicted response to immune checkpoint blockade (ICB) treatment, characterized by enrichment in M0 macrophages.
Meeting Abstract
Oncology
A. Y. Jia, Y. Sun, A. Baydoun, N. G. Zaorsky, R. A. Vince, J. E. Shoag, J. Brown, P. Barata, R. T. Dess, W. C. Jackson, S. Roy, P. L. Nguyen, A. Berlin, R. Mehra, E. M. Schaeffer, R. Kashani, A. U. Kishan, T. M. Morgan, D. E. Spratt
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Meeting Abstract
Oncology
Anna Couvillon, Baris Turkbey, Peter L. Choyke, Katherine Lee-Wisdom, Yolanda McKinney, Robert Sidlow, Michael P. Mullane, Veda N. Giri, Todd Matthew Morgan, Heather H. Cheng, Maria J. Merino, William Douglas Figg, Peter A. Pinto, William L. Dahut, Fatima Karzai
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Udit Singhal, Stephanie Daignault-Newton, Rodney Dunn, Daniel Eidelberg Spratt, Linda Okoth, Felix Y. Feng, Anna Johnson, Brian R. Lane, Susan Linsell, Ghani Khurshid, Rohit Mehra, Elai Davicioni, Thomas Maatman, Frank Burks, Paul Rodriguez, Eduardo Kleer, Richard Sarle, David Christopher Miller, Michael L. Cher, Todd Matthew Morgan
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Daniel Eidelberg Spratt, Vinnie Yt Liu, Rikiya Yamashita, Emmalyn Chen, Sandy DeVries, Ashley Ross, Angela Jia, Todd Matthew Morgan, Seth A. Rosenthal, Howard M. Sandler, Osama Mohamad, Andre Esteva, Jedidiah Mercer Monson, Steven J. Chmura, John H. Carson, Alan C. Hartford, Albert J. Chang, Stephanie L. Pugh, Phuoc T. Tran, Felix Y. Feng
JOURNAL OF CLINICAL ONCOLOGY
(2023)